nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—CYP2C19—Teniposide—lymphatic system cancer	0.137	0.439	CbGbCtD
Gliclazide—CYP2C9—Teniposide—lymphatic system cancer	0.114	0.365	CbGbCtD
Gliclazide—ALB—Methotrexate—lymphatic system cancer	0.0616	0.197	CbGbCtD
Gliclazide—Flushing—Carmustine—lymphatic system cancer	0.00114	0.00165	CcSEcCtD
Gliclazide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00113	0.00165	CcSEcCtD
Gliclazide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00113	0.00164	CcSEcCtD
Gliclazide—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00113	0.00164	CcSEcCtD
Gliclazide—Anaemia—Bleomycin—lymphatic system cancer	0.00113	0.00164	CcSEcCtD
Gliclazide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00112	0.00163	CcSEcCtD
Gliclazide—Asthenia—Teniposide—lymphatic system cancer	0.00111	0.00161	CcSEcCtD
Gliclazide—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.0011	0.0016	CcSEcCtD
Gliclazide—Melaena—Methotrexate—lymphatic system cancer	0.0011	0.0016	CcSEcCtD
Gliclazide—Malaise—Bleomycin—lymphatic system cancer	0.0011	0.0016	CcSEcCtD
Gliclazide—Pruritus—Teniposide—lymphatic system cancer	0.00109	0.00159	CcSEcCtD
Gliclazide—Arrhythmia—Carmustine—lymphatic system cancer	0.00109	0.00159	CcSEcCtD
Gliclazide—Leukopenia—Bleomycin—lymphatic system cancer	0.00109	0.00159	CcSEcCtD
Gliclazide—Cystitis—Methotrexate—lymphatic system cancer	0.00109	0.00159	CcSEcCtD
Gliclazide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00107	0.00156	CcSEcCtD
Gliclazide—Mental disorder—Carmustine—lymphatic system cancer	0.00107	0.00156	CcSEcCtD
Gliclazide—Vaginal infection—Methotrexate—lymphatic system cancer	0.00107	0.00155	CcSEcCtD
Gliclazide—Erythema—Carmustine—lymphatic system cancer	0.00106	0.00155	CcSEcCtD
Gliclazide—Malnutrition—Carmustine—lymphatic system cancer	0.00106	0.00155	CcSEcCtD
Gliclazide—Cough—Bleomycin—lymphatic system cancer	0.00106	0.00155	CcSEcCtD
Gliclazide—Diarrhoea—Teniposide—lymphatic system cancer	0.00106	0.00154	CcSEcCtD
Gliclazide—Chest pain—Bleomycin—lymphatic system cancer	0.00104	0.00151	CcSEcCtD
Gliclazide—Myalgia—Bleomycin—lymphatic system cancer	0.00104	0.00151	CcSEcCtD
Gliclazide—Coma—Methotrexate—lymphatic system cancer	0.00103	0.0015	CcSEcCtD
Gliclazide—Back pain—Carmustine—lymphatic system cancer	0.00103	0.0015	CcSEcCtD
Gliclazide—Discomfort—Bleomycin—lymphatic system cancer	0.00103	0.00149	CcSEcCtD
Gliclazide—Mental disorder—Vincristine—lymphatic system cancer	0.00102	0.00149	CcSEcCtD
Gliclazide—Chills—Mitoxantrone—lymphatic system cancer	0.00102	0.00148	CcSEcCtD
Gliclazide—Neoplasm—Methotrexate—lymphatic system cancer	0.00102	0.00148	CcSEcCtD
Gliclazide—Bladder pain—Methotrexate—lymphatic system cancer	0.00102	0.00148	CcSEcCtD
Gliclazide—Urine output increased—Methotrexate—lymphatic system cancer	0.00102	0.00148	CcSEcCtD
Gliclazide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00102	0.00148	CcSEcCtD
Gliclazide—Confusional state—Bleomycin—lymphatic system cancer	0.001	0.00146	CcSEcCtD
Gliclazide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.001	0.00146	CcSEcCtD
Gliclazide—Tremor—Carmustine—lymphatic system cancer	0.000998	0.00145	CcSEcCtD
Gliclazide—Erythema—Mitoxantrone—lymphatic system cancer	0.00099	0.00144	CcSEcCtD
Gliclazide—Infection—Bleomycin—lymphatic system cancer	0.000989	0.00144	CcSEcCtD
Gliclazide—Anaemia—Carmustine—lymphatic system cancer	0.000984	0.00143	CcSEcCtD
Gliclazide—Back pain—Vincristine—lymphatic system cancer	0.000983	0.00143	CcSEcCtD
Gliclazide—Vomiting—Teniposide—lymphatic system cancer	0.000982	0.00143	CcSEcCtD
Gliclazide—Agitation—Carmustine—lymphatic system cancer	0.000979	0.00142	CcSEcCtD
Gliclazide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000975	0.00142	CcSEcCtD
Gliclazide—Asthenia—Fludarabine—lymphatic system cancer	0.000974	0.00142	CcSEcCtD
Gliclazide—Rash—Teniposide—lymphatic system cancer	0.000974	0.00142	CcSEcCtD
Gliclazide—Dermatitis—Teniposide—lymphatic system cancer	0.000973	0.00142	CcSEcCtD
Gliclazide—Headache—Teniposide—lymphatic system cancer	0.000968	0.00141	CcSEcCtD
Gliclazide—Pruritus—Fludarabine—lymphatic system cancer	0.000961	0.0014	CcSEcCtD
Gliclazide—Back pain—Mitoxantrone—lymphatic system cancer	0.000958	0.00139	CcSEcCtD
Gliclazide—Leukopenia—Carmustine—lymphatic system cancer	0.000953	0.00139	CcSEcCtD
Gliclazide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000946	0.00138	CcSEcCtD
Gliclazide—Anaemia—Vincristine—lymphatic system cancer	0.000939	0.00137	CcSEcCtD
Gliclazide—Agitation—Vincristine—lymphatic system cancer	0.000934	0.00136	CcSEcCtD
Gliclazide—Photosensitivity—Methotrexate—lymphatic system cancer	0.000933	0.00136	CcSEcCtD
Gliclazide—Polyuria—Methotrexate—lymphatic system cancer	0.000933	0.00136	CcSEcCtD
Gliclazide—Hypotension—Bleomycin—lymphatic system cancer	0.00093	0.00135	CcSEcCtD
Gliclazide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000929	0.00135	CcSEcCtD
Gliclazide—Convulsion—Carmustine—lymphatic system cancer	0.000923	0.00134	CcSEcCtD
Gliclazide—Hypertension—Carmustine—lymphatic system cancer	0.000919	0.00134	CcSEcCtD
Gliclazide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000918	0.00134	CcSEcCtD
Gliclazide—Nausea—Teniposide—lymphatic system cancer	0.000918	0.00134	CcSEcCtD
Gliclazide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000915	0.00133	CcSEcCtD
Gliclazide—Hepatic failure—Methotrexate—lymphatic system cancer	0.000911	0.00133	CcSEcCtD
Gliclazide—Leukopenia—Vincristine—lymphatic system cancer	0.00091	0.00132	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000907	0.00132	CcSEcCtD
Gliclazide—Chest pain—Carmustine—lymphatic system cancer	0.000907	0.00132	CcSEcCtD
Gliclazide—Myalgia—Carmustine—lymphatic system cancer	0.000907	0.00132	CcSEcCtD
Gliclazide—Anxiety—Carmustine—lymphatic system cancer	0.000903	0.00131	CcSEcCtD
Gliclazide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000894	0.0013	CcSEcCtD
Gliclazide—Malaise—Mitoxantrone—lymphatic system cancer	0.000893	0.0013	CcSEcCtD
Gliclazide—Dyspnoea—Bleomycin—lymphatic system cancer	0.000888	0.00129	CcSEcCtD
Gliclazide—Renal failure acute—Methotrexate—lymphatic system cancer	0.000887	0.00129	CcSEcCtD
Gliclazide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000886	0.00129	CcSEcCtD
Gliclazide—Convulsion—Vincristine—lymphatic system cancer	0.000881	0.00128	CcSEcCtD
Gliclazide—Hypertension—Vincristine—lymphatic system cancer	0.000878	0.00128	CcSEcCtD
Gliclazide—Confusional state—Carmustine—lymphatic system cancer	0.000876	0.00127	CcSEcCtD
Gliclazide—Myalgia—Vincristine—lymphatic system cancer	0.000865	0.00126	CcSEcCtD
Gliclazide—Visual disturbance—Methotrexate—lymphatic system cancer	0.000864	0.00126	CcSEcCtD
Gliclazide—Cough—Mitoxantrone—lymphatic system cancer	0.000864	0.00126	CcSEcCtD
Gliclazide—Infection—Carmustine—lymphatic system cancer	0.000863	0.00126	CcSEcCtD
Gliclazide—Vomiting—Fludarabine—lymphatic system cancer	0.000863	0.00126	CcSEcCtD
Gliclazide—Convulsion—Mitoxantrone—lymphatic system cancer	0.000858	0.00125	CcSEcCtD
Gliclazide—Rash—Fludarabine—lymphatic system cancer	0.000856	0.00125	CcSEcCtD
Gliclazide—Dermatitis—Fludarabine—lymphatic system cancer	0.000855	0.00124	CcSEcCtD
Gliclazide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000855	0.00124	CcSEcCtD
Gliclazide—Pain—Bleomycin—lymphatic system cancer	0.000851	0.00124	CcSEcCtD
Gliclazide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000851	0.00124	CcSEcCtD
Gliclazide—Headache—Fludarabine—lymphatic system cancer	0.000851	0.00124	CcSEcCtD
Gliclazide—Tachycardia—Carmustine—lymphatic system cancer	0.000848	0.00123	CcSEcCtD
Gliclazide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000843	0.00123	CcSEcCtD
Gliclazide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000843	0.00123	CcSEcCtD
Gliclazide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000843	0.00123	CcSEcCtD
Gliclazide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00084	0.00122	CcSEcCtD
Gliclazide—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000836	0.00122	CcSEcCtD
Gliclazide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000833	0.00121	CcSEcCtD
Gliclazide—Infection—Vincristine—lymphatic system cancer	0.000824	0.0012	CcSEcCtD
Gliclazide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00082	0.00119	CcSEcCtD
Gliclazide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000819	0.00119	CcSEcCtD
Gliclazide—Confusional state—Mitoxantrone—lymphatic system cancer	0.000815	0.00119	CcSEcCtD
Gliclazide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000814	0.00118	CcSEcCtD
Gliclazide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000812	0.00118	CcSEcCtD
Gliclazide—Hypotension—Carmustine—lymphatic system cancer	0.000812	0.00118	CcSEcCtD
Gliclazide—Nausea—Fludarabine—lymphatic system cancer	0.000807	0.00117	CcSEcCtD
Gliclazide—Infection—Mitoxantrone—lymphatic system cancer	0.000803	0.00117	CcSEcCtD
Gliclazide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000802	0.00117	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000792	0.00115	CcSEcCtD
Gliclazide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000791	0.00115	CcSEcCtD
Gliclazide—Urticaria—Bleomycin—lymphatic system cancer	0.000791	0.00115	CcSEcCtD
Gliclazide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000788	0.00115	CcSEcCtD
Gliclazide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000787	0.00115	CcSEcCtD
Gliclazide—Insomnia—Carmustine—lymphatic system cancer	0.000786	0.00114	CcSEcCtD
Gliclazide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000785	0.00114	CcSEcCtD
Gliclazide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000781	0.00114	CcSEcCtD
Gliclazide—Paraesthesia—Carmustine—lymphatic system cancer	0.00078	0.00114	CcSEcCtD
Gliclazide—Hypotension—Vincristine—lymphatic system cancer	0.000775	0.00113	CcSEcCtD
Gliclazide—Dyspnoea—Carmustine—lymphatic system cancer	0.000775	0.00113	CcSEcCtD
Gliclazide—Somnolence—Carmustine—lymphatic system cancer	0.000773	0.00112	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000756	0.0011	CcSEcCtD
Gliclazide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000755	0.0011	CcSEcCtD
Gliclazide—Insomnia—Vincristine—lymphatic system cancer	0.00075	0.00109	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00075	0.00109	CcSEcCtD
Gliclazide—Paraesthesia—Vincristine—lymphatic system cancer	0.000745	0.00108	CcSEcCtD
Gliclazide—Constipation—Carmustine—lymphatic system cancer	0.000743	0.00108	CcSEcCtD
Gliclazide—Pain—Carmustine—lymphatic system cancer	0.000743	0.00108	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000737	0.00107	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000736	0.00107	CcSEcCtD
Gliclazide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000733	0.00107	CcSEcCtD
Gliclazide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000725	0.00106	CcSEcCtD
Gliclazide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00072	0.00105	CcSEcCtD
Gliclazide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000718	0.00104	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000716	0.00104	CcSEcCtD
Gliclazide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000716	0.00104	CcSEcCtD
Gliclazide—Fatigue—Vincristine—lymphatic system cancer	0.000715	0.00104	CcSEcCtD
Gliclazide—Asthenia—Bleomycin—lymphatic system cancer	0.000714	0.00104	CcSEcCtD
Gliclazide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000711	0.00103	CcSEcCtD
Gliclazide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000711	0.00103	CcSEcCtD
Gliclazide—Pain—Vincristine—lymphatic system cancer	0.000709	0.00103	CcSEcCtD
Gliclazide—Constipation—Vincristine—lymphatic system cancer	0.000709	0.00103	CcSEcCtD
Gliclazide—Asthma—Methotrexate—lymphatic system cancer	0.000708	0.00103	CcSEcCtD
Gliclazide—Pruritus—Bleomycin—lymphatic system cancer	0.000704	0.00102	CcSEcCtD
Gliclazide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000697	0.00101	CcSEcCtD
Gliclazide—Constipation—Mitoxantrone—lymphatic system cancer	0.000691	0.00101	CcSEcCtD
Gliclazide—Pain—Mitoxantrone—lymphatic system cancer	0.000691	0.00101	CcSEcCtD
Gliclazide—Abdominal pain—Carmustine—lymphatic system cancer	0.000687	0.000999	CcSEcCtD
Gliclazide—Body temperature increased—Carmustine—lymphatic system cancer	0.000687	0.000999	CcSEcCtD
Gliclazide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000679	0.000987	CcSEcCtD
Gliclazide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000678	0.000987	CcSEcCtD
Gliclazide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000672	0.000978	CcSEcCtD
Gliclazide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000666	0.000969	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000661	0.000961	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000658	0.000957	CcSEcCtD
Gliclazide—Body temperature increased—Vincristine—lymphatic system cancer	0.000656	0.000954	CcSEcCtD
Gliclazide—Abdominal pain—Vincristine—lymphatic system cancer	0.000656	0.000954	CcSEcCtD
Gliclazide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000652	0.000948	CcSEcCtD
Gliclazide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000646	0.00094	CcSEcCtD
Gliclazide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000642	0.000934	CcSEcCtD
Gliclazide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00064	0.000932	CcSEcCtD
Gliclazide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000639	0.000929	CcSEcCtD
Gliclazide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000639	0.000929	CcSEcCtD
Gliclazide—Pneumonia—Methotrexate—lymphatic system cancer	0.000635	0.000924	CcSEcCtD
Gliclazide—Vomiting—Bleomycin—lymphatic system cancer	0.000633	0.000921	CcSEcCtD
Gliclazide—Drowsiness—Methotrexate—lymphatic system cancer	0.000631	0.000918	CcSEcCtD
Gliclazide—Depression—Methotrexate—lymphatic system cancer	0.000629	0.000916	CcSEcCtD
Gliclazide—Rash—Bleomycin—lymphatic system cancer	0.000628	0.000913	CcSEcCtD
Gliclazide—Dermatitis—Bleomycin—lymphatic system cancer	0.000627	0.000912	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000626	0.00091	CcSEcCtD
Gliclazide—Asthenia—Carmustine—lymphatic system cancer	0.000624	0.000907	CcSEcCtD
Gliclazide—Renal failure—Methotrexate—lymphatic system cancer	0.00062	0.000903	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000613	0.000893	CcSEcCtD
Gliclazide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000611	0.000889	CcSEcCtD
Gliclazide—Sweating—Methotrexate—lymphatic system cancer	0.000605	0.00088	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000597	0.000868	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—lymphatic system cancer	0.000595	0.000866	CcSEcCtD
Gliclazide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000595	0.000866	CcSEcCtD
Gliclazide—Asthenia—Vincristine—lymphatic system cancer	0.000595	0.000866	CcSEcCtD
Gliclazide—Diarrhoea—Carmustine—lymphatic system cancer	0.000595	0.000865	CcSEcCtD
Gliclazide—Nausea—Bleomycin—lymphatic system cancer	0.000591	0.00086	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000589	0.000857	CcSEcCtD
Gliclazide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00058	0.000843	CcSEcCtD
Gliclazide—Dizziness—Carmustine—lymphatic system cancer	0.000575	0.000836	CcSEcCtD
Gliclazide—Diarrhoea—Vincristine—lymphatic system cancer	0.000568	0.000826	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—lymphatic system cancer	0.000567	0.000824	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000562	0.000818	CcSEcCtD
Gliclazide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000553	0.000804	CcSEcCtD
Gliclazide—Vomiting—Carmustine—lymphatic system cancer	0.000553	0.000804	CcSEcCtD
Gliclazide—Dizziness—Vincristine—lymphatic system cancer	0.000549	0.000798	CcSEcCtD
Gliclazide—Rash—Carmustine—lymphatic system cancer	0.000548	0.000797	CcSEcCtD
Gliclazide—Dermatitis—Carmustine—lymphatic system cancer	0.000547	0.000796	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—lymphatic system cancer	0.000546	0.000794	CcSEcCtD
Gliclazide—Headache—Carmustine—lymphatic system cancer	0.000544	0.000792	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000536	0.000779	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—lymphatic system cancer	0.000529	0.00077	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—lymphatic system cancer	0.000528	0.000769	CcSEcCtD
Gliclazide—Vomiting—Vincristine—lymphatic system cancer	0.000527	0.000767	CcSEcCtD
Gliclazide—Rash—Vincristine—lymphatic system cancer	0.000523	0.000761	CcSEcCtD
Gliclazide—Dermatitis—Vincristine—lymphatic system cancer	0.000523	0.00076	CcSEcCtD
Gliclazide—Headache—Vincristine—lymphatic system cancer	0.00052	0.000756	CcSEcCtD
Gliclazide—Nausea—Carmustine—lymphatic system cancer	0.000516	0.000751	CcSEcCtD
Gliclazide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000514	0.000747	CcSEcCtD
Gliclazide—Rash—Mitoxantrone—lymphatic system cancer	0.000509	0.000741	CcSEcCtD
Gliclazide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000509	0.00074	CcSEcCtD
Gliclazide—Chills—Methotrexate—lymphatic system cancer	0.000508	0.00074	CcSEcCtD
Gliclazide—Headache—Mitoxantrone—lymphatic system cancer	0.000506	0.000736	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—lymphatic system cancer	0.000496	0.000722	CcSEcCtD
Gliclazide—Erythema—Methotrexate—lymphatic system cancer	0.000493	0.000718	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—lymphatic system cancer	0.000493	0.000718	CcSEcCtD
Gliclazide—Nausea—Vincristine—lymphatic system cancer	0.000493	0.000717	CcSEcCtD
Gliclazide—Nausea—Mitoxantrone—lymphatic system cancer	0.00048	0.000698	CcSEcCtD
Gliclazide—Back pain—Methotrexate—lymphatic system cancer	0.000477	0.000694	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000458	0.000666	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—lymphatic system cancer	0.000456	0.000663	CcSEcCtD
Gliclazide—Malaise—Methotrexate—lymphatic system cancer	0.000445	0.000647	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—lymphatic system cancer	0.000441	0.000642	CcSEcCtD
Gliclazide—Cough—Methotrexate—lymphatic system cancer	0.00043	0.000626	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—lymphatic system cancer	0.000427	0.000622	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—lymphatic system cancer	0.00042	0.000611	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—lymphatic system cancer	0.00042	0.000611	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—lymphatic system cancer	0.00042	0.000611	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000417	0.000607	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—lymphatic system cancer	0.000415	0.000604	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—lymphatic system cancer	0.000406	0.00059	CcSEcCtD
Gliclazide—Infection—Methotrexate—lymphatic system cancer	0.0004	0.000582	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000395	0.000574	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000394	0.000573	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—lymphatic system cancer	0.000391	0.000569	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000389	0.000566	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—lymphatic system cancer	0.000376	0.000547	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000367	0.000534	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—lymphatic system cancer	0.000364	0.00053	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000361	0.000526	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000359	0.000522	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—lymphatic system cancer	0.000358	0.000521	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000354	0.000516	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000348	0.000506	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—lymphatic system cancer	0.000347	0.000505	CcSEcCtD
Gliclazide—Pain—Methotrexate—lymphatic system cancer	0.000344	0.000501	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000332	0.000483	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000329	0.000479	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—lymphatic system cancer	0.00032	0.000465	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000318	0.000463	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000318	0.000463	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000297	0.000431	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—lymphatic system cancer	0.000289	0.00042	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—lymphatic system cancer	0.000285	0.000414	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000275	0.000401	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—lymphatic system cancer	0.000266	0.000387	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—lymphatic system cancer	0.000256	0.000372	CcSEcCtD
Gliclazide—Rash—Methotrexate—lymphatic system cancer	0.000254	0.000369	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—lymphatic system cancer	0.000254	0.000369	CcSEcCtD
Gliclazide—Headache—Methotrexate—lymphatic system cancer	0.000252	0.000367	CcSEcCtD
Gliclazide—Nausea—Methotrexate—lymphatic system cancer	0.000239	0.000348	CcSEcCtD
